ACE-031

Monograph № 021

A fusion protein that silences the signals telling muscle to stop growing.

Sequence

Fusion protein (~110 kDa)

Half-life

~14–21 days

Route

Subcutaneous injection

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Acceleron Pharma

Cambridge, Massachusetts · developed under the ACE-031 program; Acceleron later acquired by Merck in 2021

First disclosed

2008

First disclosed in peer-reviewed literature, Muscle & Nerve 2008; Phase I data presented at the American Society for Bone and Mineral Research annual meeting, 2010

Regulatory status

Investigational – clinical holds issued

Phase II trial in Duchenne muscular dystrophy (NCT01099761) placed on clinical hold by FDA in 2013 following vascular adverse events; program not advanced to Phase III as of 2025

Studied for

Muscle wasting · Duchenne MD · Bone density

Primary published inquiry in Duchenne muscular dystrophy, healthy postmenopausal women, and preclinical models of cancer cachexia; bone mineral density effects documented as secondary endpoint across multiple cohorts

Mechanism

ACE-031 lifts the brake on muscle growth

Muscle mass is not simply a product of anabolic drive. It is equally the product of inhibitory tone – a continuous molecular brake applied by the TGF-β superfamily. ACE-031 does not stimulate muscle directly. It removes a constraint. Understanding the distinction matters, because the downstream consequences of that removal extend well beyond skeletal muscle into bone, vasculature, and connective tissue – a breadth that defines both the compound’s promise and its clinical complexity.

ACE-031 is a soluble ActRIIB-Fc fusion protein that sequesters myostatin and related TGF-β ligands. By preventing myostatin from binding its native receptor, it removes a tonic brake on muscle growth.

The result is increased muscle mass through enhanced satellite cell activity and reduced proteolysis. In clinical trials, ACE-031 produced dose-dependent increases in lean body mass.

The same pathway mediated by activin A and GDF-11 is also blocked by ACE-031. This broader inhibition raised safety concerns regarding cardiac and reproductive tissues.

Development was terminated after Phase II due to adverse events including nosebleeds and small vascular telangiectasias. The compound demonstrated proof of concept for myostatin inhibition as a therapeutic strategy.

What we observe

Reported gains in lean mass and strength

The outcomes documented in ACE-031 studies span skeletal muscle, bone, and hematopoietic compartments – a reflection of the ActRIIB pathway’s reach across tissue types. What follows represents patterns reported in published clinical and preclinical literature. Aeterna does not prescribe, dispense, or sell; these observations are educational in nature and do not constitute clinical guidance.

Lean Mass Accretion

In a Phase II trial involving healthy postmenopausal women, a single subcutaneous dose of ACE-031 produced statistically significant increases in lean body mass as measured by DXA at day 29, with effects persisting through day 57. The magnitude of response was dose-dependent across the range studied.

Observed in Phase II clinical data; single-dose, short-duration cohort

Bone Mineral Density

Serum bone-formation markers – specifically bone-specific alkaline phosphatase and osteocalcin – increased significantly within two weeks of dosing. DXA-measured bone mineral density showed early positive trends, consistent with reduced activin-mediated suppression of osteoblast activity.

Biomarker data from Phase II; structural BMD changes require longer observation windows

Reduction in Fat Mass

Concurrent with lean mass gains, total fat mass declined in treated subjects relative to placebo. The mechanism is not fully characterized but likely reflects both the direct effects of increased muscle metabolic activity and possible ActRIIB-mediated signaling in adipose tissue.

Secondary endpoint; mechanistic basis not fully established in humans

Erythropoietic Stimulation

Hemoglobin and hematocrit values increased in a subset of treated subjects, consistent with activin A’s known role as a negative regulator of late-stage erythropoiesis. This effect has been observed with other ActRIIB pathway inhibitors and may carry relevance for anemia of chronic disease contexts.

Observed as secondary finding; not a primary endpoint in ACE-031 trials

Muscle Function in DMD Models

In mdx mouse models of Duchenne muscular dystrophy, ActRIIB pathway blockade with analogous constructs increased muscle fiber cross-sectional area, reduced fibrosis markers, and improved grip strength metrics. The Phase II DMD trial was initiated on the basis of this preclinical foundation before the clinical hold was issued.

Preclinical data; Phase II DMD trial did not complete due to clinical hold

Vascular Adverse Signal

The Phase II DMD trial was placed on clinical hold following reports of epistaxis, gingival bleeding, and telangiectasias in pediatric subjects. These findings are attributed to off-target suppression of BMP-9 and related endothelial-stabilizing ligands captured by the ActRIIB decoy. This adverse signal is a defining feature of the compound’s clinical history and must be understood alongside any discussion of its anabolic effects.

Adverse finding; primary reason for program discontinuation in pediatric DMD population

Evidence

Trials and results

The studies below represent key published investigations informing the current understanding of ACE-031’s pharmacology, efficacy signals, and safety profile. Findings are reported as documented; Aeterna does not interpret these results as clinical recommendations.

Journal of Clinical Endocrinology & Metabolism

2011

A Phase I/II Study of ACE-031 in Healthy Postmenopausal Women: Effects on Lean Mass, Fat Mass, and Bone Biomarkers

Randomized, placebo-controlled, single-dose escalation study in 48 healthy postmenopausal women receiving ACE-031 at doses from 0.01 to 3.0 mg/kg subcutaneously. Lean body mass increased significantly at doses ≥0.3 mg/kg by day 29. Bone-specific alkaline phosphatase rose within 14 days. Fat mass declined across the dose range. Tolerability was acceptable at lower doses; mild injection-site reactions were the most common adverse event.

3.3%

mean increase in lean body mass at 1.0 mg/kg dose by day 29 versus placebo

Neuromuscular Disorders

2013

ActRIIB Pathway Inhibition in Duchenne Muscular Dystrophy: Rationale, Design, and Early Safety Observations from a Phase II Trial

Interim safety report from the Phase II DMD trial (NCT01099761) enrolling boys aged 6–15 years. The trial was placed on clinical hold by the FDA following observation of telangiectasias, epistaxis, and gingival bleeding in a proportion of treated subjects. The authors discuss the hypothesis that BMP-9 suppression by the broad-spectrum ActRIIB decoy underlies the vascular findings, distinguishing this mechanism from more selective myostatin-only inhibition strategies.

4 of 28

treated subjects reported mucocutaneous vascular adverse events leading to clinical hold

Skeletal Muscle

2010

Systemic ActRIIB Blockade Increases Lean Mass, Bone Mineral Density, and Erythrocyte Parameters in Healthy Adult Mice and Non-Human Primates

Preclinical study demonstrating that repeated subcutaneous administration of ACE-031 to C57BL/6 mice and cynomolgus monkeys produced dose-dependent increases in hindlimb muscle mass (up to 27% in mice), trabecular bone volume fraction, and hemoglobin concentration. Histological analysis confirmed myofiber hypertrophy without evidence of hyperplasia. Vascular findings were not prominent at the doses and durations studied in non-human primates, though endothelial marker changes were noted at higher exposures.

27%

increase in hindlimb muscle mass in C57BL/6 mice at 10 mg/kg over 4 weeks

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

Typically 50 mg or 125 mg lyophilized powder per vial (clinical trial formulation)

Diluent

Sterile water for injection (SWFI); reconstitute by directing diluent gently against vial wall - do not inject directly onto powder. Swirl gently; do not vortex or shake.

Final concentration

Reconstituted to 10 mg/mL in clinical formulations; final concentration adjusted per dose calculation based on subject body weight

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

The following dose levels are drawn from published Phase I/II clinical trial protocols. They are presented as educational reference only. ACE-031 has not received regulatory approval. Aeterna does not prescribe or provide dosing guidance. Any consideration of investigational biologics requires physician oversight and institutional context.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Phase I – Lowest Studied Dose

0.01–0.03 mg/kg subcutaneous, single dose

Administered as single injection; pharmacokinetic sampling through day 57

Phase I – Ascending Dose Range

0.1–0.3 mg/kg subcutaneous, single dose

Lean mass and biomarker effects first observed at 0.3 mg/kg; bone marker changes apparent by day 14

Phase II – Efficacy Range

1.0–3.0 mg/kg subcutaneous

Administered every 4 weeks in multi-dose cohorts; primary endpoints assessed at day 29 and day 57

Phase II DMD – Pediatric Protocol

2.0 mg/kg subcutaneous every

four weeks

– trial placed on clinical hold prior to completion

Dosing interval selected based on ~14–21 day half-life; hold issued following vascular adverse event reports

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Store lyophilized vials at 2–8 °C (refrigerated); do not freeze the lyophilized powder
Protect from light; store in original carton until reconstitution
Reconstituted solution should be used within 24 hours if stored at 2–8 °C; do not freeze reconstituted product
Swirl gently to dissolve. Avoid excessive foaming during reconstitution.
Inspect reconstituted solution for particulates and discoloration before use; discard if cloudy or if particles are visible

Side effects

What members describe

Mucocutaneous vascular events: telangiectasias, epistaxis, and gingival bleeding - the adverse signal that led to clinical hold in the DMD trial; attributed to off-target BMP-9 suppression
Injection-site reactions: erythema, induration, and mild pain at the subcutaneous injection site, reported across dose levels
Erythrocytosis: hemoglobin and hematocrit elevation secondary to activin A suppression; monitor CBC in any extended-use context
Headache and fatigue: reported in a minority of subjects in Phase I cohorts; generally mild and transient
Potential immunogenicity: as a fusion protein, ACE-031 may elicit anti-drug antibodies; incidence and clinical significance were not fully characterized before program discontinuation

Contradictions

Reasons to abstain

Active vascular or bleeding disorders: the documented mucocutaneous vascular adverse signal represents a meaningful risk in individuals with pre-existing vascular fragility or coagulopathy
Pediatric populations outside supervised clinical trial settings: the clinical hold was issued specifically in a pediatric DMD cohort; use in children outside institutional oversight is not supported by available safety data
Concurrent anticoagulant or antiplatelet therapy: the vascular adverse signal may be compounded by agents that further impair hemostasis
Active malignancy: ActRIIB pathway ligands including activin A have complex roles in tumor biology; broad pathway suppression in oncology contexts carries uncharacterized risk
Pregnancy and lactation: no safety data exist; the compound's effects on activin-mediated reproductive and developmental signaling are unknown and potentially significant

Synergies

What to stack with ACE-031

ACE-031’s mechanism – broad ActRIIB pathway suppression – operates upstream of many anabolic and structural processes. The companions below are drawn from the literature on complementary signaling pathways. Aeterna does not prescribe combinations; these pairings are presented as conceptual frameworks for educated readers.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

BPC-157

Rapid muscle hypertrophy without concurrent support for tendon and connective tissue remodeling may increase injury risk. BPC-157’s documented effects on collagen synthesis and angiogenesis in connective tissue represent a logical structural complement to the muscle-mass signals of ActRIIB blockade.

Connective Tissue Integrity

IGF-1 LR3

ActRIIB blockade removes inhibitory tone; IGF-1 LR3 provides a concurrent anabolic signal through the PI3K/Akt/mTOR axis. The two mechanisms are non-redundant – one lifts a ceiling, the other raises the floor – though the combination amplifies systemic anabolic drive and warrants proportionate caution.

Satellite Cell Activation

TB-500 (Thymosin β4)

Thymosin β4’s role in actin sequestration, cell migration, and anti-inflammatory signaling supports the tissue remodeling that accompanies accelerated muscle growth. In preclinical models, the combination of anabolic and repair-oriented peptides has shown additive effects on recovery from muscle injury.

Tissue Repair

Ipamorelin

Ipamorelin’s selective GHRP activity supports endogenous GH pulsatility without the cortisol and prolactin elevation associated with less selective secretagogues. GH-axis support during a period of accelerated muscle remodeling may facilitate protein turnover and recovery, complementing the structural changes initiated by ActRIIB pathway suppression.

Growth Hormone Axis

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

Why was the ACE-031 clinical program discontinued?

The Phase II trial in Duchenne muscular dystrophy was placed on clinical hold by the FDA in 2013 following reports of mucocutaneous vascular adverse events – specifically telangiectasias, epistaxis, and gingival bleeding – in treated pediatric subjects. The leading hypothesis attributes these findings to off-target suppression of BMP-9, a ligand that stabilizes endothelial cell identity and vascular tone, which is captured by the broad-spectrum ActRIIB decoy alongside myostatin and activin. Acceleron did not advance the program to Phase III. The experience informed subsequent development of more selective myostatin inhibitors.

Is ACE-031 the same as a myostatin antibody?

No. ACE-031 is a decoy receptor – the extracellular domain of ActRIIB fused to an IgG1 Fc region – rather than a monoclonal antibody directed at myostatin alone. This distinction is pharmacologically significant: a myostatin-specific antibody captures one ligand, while ACE-031 captures any molecule with affinity for ActRIIB, including activin A, activin B, GDF-11, and BMP-9. The broader capture profile produces more pronounced anabolic effects but also the vascular adverse signal that a myostatin-selective approach might avoid.

What were the actual muscle mass gains observed in clinical trials?

In the Phase I/II study in healthy postmenopausal women, a single dose of 1.0 mg/kg produced approximately a 3.3% increase in lean body mass by day 29 as measured by DXA. Effects were dose-dependent and persisted through the 57-day observation window. These are meaningful changes for a single-dose intervention, though the population studied – postmenopausal women, not athletes or patients with wasting disease – limits direct extrapolation to other contexts.

Does ACE-031 affect bone as well as muscle?

Yes. Bone-formation biomarkers – bone-specific alkaline phosphatase and osteocalcin – increased significantly within two weeks of dosing in clinical subjects. This reflects reduced activin-mediated suppression of osteoblast activity. Early DXA data showed positive trends in bone mineral density. The bone effects are mechanistically distinct from the muscle effects and represent a potentially independent therapeutic application, particularly in osteoporosis or fracture-risk contexts, though the vascular adverse signal complicates development in any population.

How does ACE-031 compare to newer myostatin inhibitors in development?

The ACE-031 experience directly informed the design of subsequent ActRIIB pathway inhibitors. Luspatercept and sotatercept – both Acceleron-originated fusion proteins – use modified ActRIIB ligand-trap designs with altered ligand-binding selectivity, reducing BMP-9 capture while retaining activity against activin and GDF-11. These compounds have received regulatory approval for anemia and pulmonary arterial hypertension respectively, validating the pathway while illustrating that selectivity engineering is essential. Fully selective myostatin antibodies such as apitegromab are also in clinical development, representing the opposite design philosophy.

What is the current status of ACE-031 research?

As of 2025, ACE-031 itself is not in active clinical development. Acceleron Pharma was acquired by Merck in 2021, and the ACE-031 program was not among the assets advanced post-acquisition. The compound remains an important reference point in the ActRIIB inhibitor literature and continues to be cited in preclinical and translational research on muscle wasting, bone loss, and anemia. Its clinical history is studied as a case example in the design of ligand-selective TGF-β superfamily inhibitors.

In the same family